Stay updated with breaking news from Mild Asthma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and...
The study states that indoor air pollution caused by fumes can lead to irritation and inflammation in people with mild asthma. | Health
The MHRA has approved the first dual-combination, inhaled corticosteroid and long-acting beta2-agonist reliever therapy for mild asthma.
an anti-inflammatory reliever in mild asthma therapy approved in China for mild, moderate and severe asthma AstraZeneca's Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older. The approval by the National Medical Products Administration (NMPA) was based on positive results from the SYGMA 1 and SYGMA 2 Phase III trials, published in The...